SC
LBRX

Stempoint Capital’s LB Pharmaceuticals LBRX Stock Holding History

Stempoint Capital’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
31,785
-18,215
-36% -$535K 0.18% 70
2026
Q1 		$1.23M Buy
+50,000
New +$1.15M 0.24% 63

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Stempoint Capital's LBRX Position: Q2 2026 in Review

Stempoint Capital reduced its LB Pharmaceuticals (LBRX) stake by 36% in Q2 2026, selling an estimated $535K and leaving 31,785 shares worth $1.03M. The position accounts for 0.18% of the portfolio, ranked #70.

Stempoint Capital first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.23M in Q1 2026. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Stempoint Capital held 31,785 shares of LB Pharmaceuticals worth $1.03M as of Q2 2026.
  • Stempoint Capital sold 18,215 LB Pharmaceuticals shares in Q2 2026, an estimated $535K.
  • LB Pharmaceuticals made up 0.18% of Stempoint Capital's portfolio in Q2 2026, its #70 holding.
  • Stempoint Capital first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Stempoint Capital's LB Pharmaceuticals position peaked at $1.23M in Q1 2026.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.